Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Galderma receives Clobex approval

Galderma receives Clobex approval

2nd November 2005

The FDA has granted Galderma Laboratories received approval to market its Clobex spray, for the treatment of moderate-to-severe plaque psoriasis. The treatment delivers the active ingredient clobetasol in a spray formulation.

Two multi-centre, randomised, double-blind studies involving 209 patients with moderate-to-severe psoriasis were undertaken.

In the first clinical trial, 82 per cent of patients became clear or almost clear after four weeks of treatment, with 47 per cent of these subjects becoming clear or almost clear in as early as two weeks. In a second study, 78 per cent of patients were clear or almost clear after four weeks.

The treatment is available by prescription. The active ingredient, Clobetasol propionate, has been shown to suppress the HPA axis at the lowest doses tested.

Galderma specialises in treatments for skin conditions and is currently focussing its marketing drive on college-age customers.

To this end it has announced a partnership with the National Psoriasis Foundation (NPF) on a first-of-its-kind survey campaign directed to college-age individuals.

“College-age individuals seem to be affected by their psoriasis in ways that are perhaps different from than other patients,” said Gail Zimmerman, Executive Director, NPF.

“This new research will allow us to better understand this very unique patient population and introduce potential strategies to minimize their social and emotional impact.”

Results of the survey are expected for release in January.

track© Adfero Ltd

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.